In Vitro Susceptibility of Respiratory Isolates of Aspergillus species to Itraconazole and Amphotericin B. Acquired Resistance to Itraconazole

References

• Bodey G P. Aspergillosis. Eur J Clin Microbiol 1989; 8: 413–37
   Google Scholar
• Horvath J A, Dummer S. The use of respiratory tract cultures in the diagnosis of invasive pulmonaty aspergillosis. Am J Med 1996; 100: 171–8
   PubMed Web of Science ®Google Scholar
• Denning D W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–15
   PubMed Web of Science ®Google Scholar
• Souha K S, Welty-Wolf K, Madden J, Tapson V, Baz M A, Davis R D, Perfect J R. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Med 1996; 75: 142–56
   PubMed Web of Science ®Google Scholar
• Denning D W, Tucker R M, Hanson L H, Stevens D A. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989; 86: 791–800
   PubMed Web of Science ®Google Scholar
• Denning D W, Lee J Y, Hostetler J S, Pappas P, Kauffman C A, Dewanup D H. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135–44
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Dawson K, Pfaller M, Anaissie E, Breslin B, Dixcn D. Comparative and collaborative evaluation of standardisation of antifungal susceptibility testing of filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314–9
   PubMed Web of Science ®Google Scholar
• Gehrt A, Peter J, Pizzo P A, Walsh T J. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol 1995; 33: 1302–7
   PubMed Web of Science ®Google Scholar
• Manavathu E K, Alangaden G J, Lerner S A. A comparative study of the broth micro-and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus. Can J Microbiol 1996; 42: 960–4
   PubMed Web of Science ®Google Scholar
• Pujol I, Guarro J, Llop C, Soler L, Fernandez-Ballart J. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi. Antimicrob Agent Chemother 1996; 40: 2106–10
   PubMed Web of Science ®Google Scholar
• Dermoumi H. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B. Chemotherapy 1994; 40: 92–8
   PubMed Web of Science ®Google Scholar
• De Hoog G S, Guarro J. Atlas of Clinical Fungi. Baarn and Delft, Centraalbureau voor Schimmelcultures. 1995
   Google Scholar
• Denning D W, Hanson L H, Stevens D A. In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species. Eur J Clin Microbiol Infect Dis 1990; 9: 693–7
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Kerkering T M. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi. J Clin Microbiol 1991; 29: 393–4
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pensylvania 1992
   Google Scholar
• Pfaller M A, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex J H, Rinaldi M G, Cooper C R, McGinnis M R. Quality control guidelines for National Committee for Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol 1995; 33: 1104–7
   PubMed Web of Science ®Google Scholar
• Rex J H, Pfaller M A, Lancaster M, Odds F C, Bolmström A, Rinaldi M G. Quality control guidelines for National Committee for Laboratory Standards-recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol 1996; 34: 816–7
   PubMed Web of Science ®Google Scholar
• Colombo A L, McGough D A, Rinaldi M G. Discrepancies between MIC and MLC values pf amphotericin B against isolates of Aspergillus species. Mycopathologia 1994; 128: 129–33
   PubMed Web of Science ®Google Scholar
• Denning D W, Hanson L H, Perlman A M, Stevens D A. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992; 15: 21–34
   PubMed Web of Science ®Google Scholar
• Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23: 607–14
   PubMed Web of Science ®Google Scholar
• Caras W E, Pluss J L. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc 1996; 71: 25–30
   PubMed Web of Science ®Google Scholar
• Sekhon A S, Padhye A A, Garg A K, Hamir Z. Effects of culture media on the in vitro susceptibility of selected opportunistic fungi to fluconazole and itraconazole. Chemotherapy 1992; 38: 169–73
   PubMed Web of Science ®Google Scholar
• Denning D W, Stevens D A. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12: 1147–201
   PubMedGoogle Scholar
• Hostetler J S, Hcykants J, Clemons K V, Woestenborghs R, Hanson L H, Stevens D A. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agent Chemother 1993; 37: 2224–7
   PubMed Web of Science ®Google Scholar